Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Rotator Cuff Tenocytes Differentiate into Hypertrophic Chondrocyte-Like Cells to Produce Calcium Deposits in an Alkaline Phosphatase-Dependent Manner.

Darrieutort-Laffite C, Arnolfo P, Garraud T, Adrait A, Couté Y, Louarn G, Trichet V, Layrolle P, Le Goff B, Blanchard F.

J Clin Med. 2019 Sep 26;8(10). pii: E1544. doi: 10.3390/jcm8101544.

2.

Immune Modulation by Transplanted Calcium Phosphate Biomaterials and Human Mesenchymal Stromal Cells in Bone Regeneration.

Humbert P, Brennan MÁ, Davison N, Rosset P, Trichet V, Blanchard F, Layrolle P.

Front Immunol. 2019 Apr 2;10:663. doi: 10.3389/fimmu.2019.00663. eCollection 2019. Review.

3.

Low-Dose Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro.

Leveque X, Hochane M, Geraldo F, Dumont S, Gratas C, Oliver L, Gaignier C, Trichet V, Layrolle P, Heymann D, Herault O, Vallette FM, Olivier C.

Stem Cells. 2019 Aug;37(8):1083-1094. doi: 10.1002/stem.3014. Epub 2019 Apr 17.

PMID:
30977188
4.

Modifying internal organization and surface morphology of siRNA lipoplexes by sodium alginate addition for efficient siRNA delivery.

Arruda DC, Gonzalez IJ, Finet S, Cordova L, Trichet V, Andrade GF, Hoffmann C, Bigey P, de Almeida Macedo WA, Da Silva Cunha A Jr, Malachias de Souza A, Escriou V.

J Colloid Interface Sci. 2019 Mar 22;540:342-353. doi: 10.1016/j.jcis.2019.01.043. Epub 2019 Jan 14.

PMID:
30660791
5.

Early Fracture Healing is Delayed in the Col1a2+/G610C Osteogenesis Imperfecta Murine Model.

Besio R, Maruelli S, Battaglia S, Leoni L, Villani S, Layrolle P, Rossi A, Trichet V, Forlino A.

Calcif Tissue Int. 2018 Dec;103(6):653-662. doi: 10.1007/s00223-018-0461-x. Epub 2018 Aug 3.

PMID:
30076439
6.

Comparison of Tumor- and Bone Marrow-Derived Mesenchymal Stromal/Stem Cells from Patients with High-Grade Osteosarcoma.

Le Nail LR, Brennan M, Rosset P, Deschaseaux F, Piloquet P, Pichon O, Le Caignec C, Crenn V, Layrolle P, Hérault O, De Pinieux G, Trichet V.

Int J Mol Sci. 2018 Mar 1;19(3). pii: E707. doi: 10.3390/ijms19030707.

7.

Inferior In Vivo Osteogenesis and Superior Angiogenesis of Human Adipose-Derived Stem Cells Compared with Bone Marrow-Derived Stem Cells Cultured in Xeno-Free Conditions.

Brennan MA, Renaud A, Guilloton F, Mebarki M, Trichet V, Sensebé L, Deschaseaux F, Chevallier N, Layrolle P.

Stem Cells Transl Med. 2018 Mar;7(3):315. doi: 10.1002/sctm.12274. No abstract available.

8.

Inferior In Vivo Osteogenesis and Superior Angiogenesis of Human Adipose‐Derived Stem Cells Compared with Bone Marrow‐Derived Stem Cells Cultured in Xeno‐Free Conditions.

Brennan MA, Renaud A, Guilloton F, Mebarki M, Trichet V, Sensebé L, Deschaseaux F, Chevallier N, Layrolle P.

Stem Cells Transl Med. 2017 Dec;6(12):2160-2172. doi: 10.1002/sctm.17-0133. Epub 2017 Oct 19. Erratum in: Stem Cells Transl Med. 2018 Mar;7(3):315.

9.

Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics.

Ratcliffe P, Koivunen P, Myllyharju J, Ragoussis J, Bovée JV, Batinic-Haberle I, Vinatier C, Trichet V, Robriquet F, Oliver L, Gardie B.

Hypoxia (Auckl). 2017 Mar 15;5:11-20. doi: 10.2147/HP.S127042. eCollection 2017. Review.

10.

IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro.

Boutet MA, Najm A, Bart G, Brion R, Touchais S, Trichet V, Layrolle P, Gabay C, Palmer G, Blanchard F, Le Goff B.

Ann Rheum Dis. 2017 Jul;76(7):1304-1312. doi: 10.1136/annrheumdis-2016-210630. Epub 2017 Mar 13.

PMID:
28288964
11.

Plasma membrane reorganization links acid sphingomyelinase/ceramide to p38 MAPK pathways in endothelial cells apoptosis.

Niaudet C, Bonnaud S, Guillonneau M, Gouard S, Gaugler MH, Dutoit S, Ripoche N, Dubois N, Trichet V, Corre I, Paris F.

Cell Signal. 2017 May;33:10-21. doi: 10.1016/j.cellsig.2017.02.001. Epub 2017 Feb 6.

PMID:
28179144
12.

Low-Dose Pesticide Mixture Induces Senescence in Normal Mesenchymal Stem Cells (MSC) and Promotes Tumorigenic Phenotype in Premalignant MSC.

Hochane M, Trichet V, Pecqueur C, Avril P, Oliver L, Denis J, Brion R, Amiaud J, Pineau A, Naveilhan P, Heymann D, Vallette FM, Olivier C.

Stem Cells. 2017 Mar;35(3):800-811. doi: 10.1002/stem.2539. Epub 2016 Nov 23.

13.

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.

Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, Moreau A, Esbelin J, Trichet V, Chen-Kiang S, Moreau P, Touzeau C, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Blood. 2016 Dec 15;128(24):2808-2818. Epub 2016 Oct 3.

PMID:
27697772
14.

Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery.

Stanovici J, Le Nail LR, Brennan MA, Vidal L, Trichet V, Rosset P, Layrolle P.

Curr Res Transl Med. 2016 Apr-Jun;64(2):83-90. doi: 10.1016/j.retram.2016.04.006. Epub 2016 Jun 1. Review.

PMID:
27316391
15.

Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status.

Avril P, Le Nail LR, Brennan MÁ, Rosset P, De Pinieux G, Layrolle P, Heymann D, Perrot P, Trichet V.

J Bone Oncol. 2015 Dec 12;5(1):5-14. doi: 10.1016/j.jbo.2015.11.002. eCollection 2016 Mar.

16.

Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells.

Avril P, Duteille F, Ridel P, Heymann MF, De Pinieux G, Rédini F, Blanchard F, Heymann D, Trichet V, Perrot P.

Plast Reconstr Surg. 2016 Mar;137(3):865-75. doi: 10.1097/01.prs.0000479989.88114.8b.

PMID:
26910666
17.

3D cell culture and osteogenic differentiation of human bone marrow stromal cells plated onto jet-sprayed or electrospun micro-fiber scaffolds.

Brennan MÁ, Renaud A, Gamblin AL, D'Arros C, Nedellec S, Trichet V, Layrolle P.

Biomed Mater. 2015 Aug 4;10(4):045019. doi: 10.1088/1748-6041/10/4/045019.

PMID:
26238732
18.

Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model.

Córdova LA, Trichet V, Escriou V, Rosset P, Amiaud J, Battaglia S, Charrier C, Berreur M, Brion R, Gouin F, Layrolle P, Passuti N, Heymann D.

Acta Biomater. 2015 Feb;13:150-8. doi: 10.1016/j.actbio.2014.10.042. Epub 2014 Nov 20.

PMID:
25462844
19.

Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate.

Brennan MÁ, Renaud A, Amiaud J, Rojewski MT, Schrezenmeier H, Heymann D, Trichet V, Layrolle P.

Stem Cell Res Ther. 2014 Oct 13;5(5):114. doi: 10.1186/scrt504.

20.

Osteoblastic and osteoclastic differentiation of human mesenchymal stem cells and monocytes in a miniaturized three-dimensional culture with mineral granules.

Gamblin AL, Renaud A, Charrier C, Hulin P, Louarn G, Heymann D, Trichet V, Layrolle P.

Acta Biomater. 2014 Dec;10(12):5139-5147. doi: 10.1016/j.actbio.2014.08.033. Epub 2014 Sep 6.

PMID:
25196309
21.

Bone tissue formation with human mesenchymal stem cells and biphasic calcium phosphate ceramics: the local implication of osteoclasts and macrophages.

Gamblin AL, Brennan MA, Renaud A, Yagita H, Lézot F, Heymann D, Trichet V, Layrolle P.

Biomaterials. 2014 Dec;35(36):9660-7. doi: 10.1016/j.biomaterials.2014.08.018. Epub 2014 Aug 29.

22.

Orthopaedic implant failure: aseptic implant loosening--the contribution and future challenges of mouse models in translational research.

Cordova LA, Stresing V, Gobin B, Rosset P, Passuti N, Gouin F, Trichet V, Layrolle P, Heymann D.

Clin Sci (Lond). 2014 Sep;127(5):277-93. doi: 10.1042/CS20130338. Review.

23.

Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta.

Rousseau J, Gioia R, Layrolle P, Lieubeau B, Heymann D, Rossi A, Marini JC, Trichet V, Forlino A.

Eur J Hum Genet. 2014 May;22(5):667-74. doi: 10.1038/ejhg.2013.198. Epub 2013 Sep 11.

24.

Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL.

Picarda G, Matous E, Amiaud J, Charrier C, Lamoureux F, Heymann MF, Tirode F, Pitard B, Trichet V, Heymann D, Redini F.

J Bone Oncol. 2013 May 20;2(3):95-104. doi: 10.1016/j.jbo.2013.04.004. eCollection 2013 Sep.

25.

Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model.

Brullé L, Vandamme M, Riès D, Martel E, Robert E, Lerondel S, Trichet V, Richard S, Pouvesle JM, Le Pape A.

PLoS One. 2012;7(12):e52653. doi: 10.1371/journal.pone.0052653. Epub 2012 Dec 26.

26.

Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells.

Bouacida A, Rosset P, Trichet V, Guilloton F, Espagnolle N, Cordonier T, Heymann D, Layrolle P, Sensébé L, Deschaseaux F.

PLoS One. 2012;7(11):e48648. doi: 10.1371/journal.pone.0048648. Epub 2012 Nov 7.

27.

Sheddable PEG for deshielding siRNA nanoparticles in the tumor acid microenvironment.

Trichet V, Layrolle P, Escriou V.

Nanomedicine (Lond). 2012 Feb;7(2):182-3. No abstract available.

PMID:
22451971
28.

Oncogene silencing by systemic delivery of lipid nanoparticle.

Trichet V, Layrolle P, Escriou V.

Nanomedicine (Lond). 2012 Feb;7(2):182. No abstract available.

PMID:
22451970
29.

Cell differentiation and osseointegration influenced by nanoscale anodized titanium surfaces.

Lavenus S, Trichet V, Le Chevalier S, Hoornaert A, Louarn G, Layrolle P.

Nanomedicine (Lond). 2012 Jul;7(7):967-80. doi: 10.2217/nnm.11.181. Epub 2012 Mar 6.

PMID:
22394187
30.

Lipid nanoparticles for siRNA delivery in lungs .

Trichet V, Layrolle P, Escriou V.

Nanomedicine (Lond). 2012 Feb;7(2):181-3. doi: 10.2217/nnm.12.4. No abstract available.

PMID:
22339131
31.

A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms.

Picarda G, Surget S, Guiho R, Téletchéa S, Berreur M, Tirode F, Pellat-Deceunynck C, Heymann D, Trichet V, Rédini F.

Mol Cancer Res. 2012 Mar;10(3):336-46. doi: 10.1158/1541-7786.MCR-11-0390. Epub 2012 Jan 18.

32.

TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.

Picarda G, Trichet V, Téletchéa S, Heymann D, Rédini F.

Am J Cancer Res. 2012;2(1):45-64. Epub 2011 Oct 9.

33.

Adhesion and osteogenic differentiation of human mesenchymal stem cells on titanium nanopores.

Lavenus S, Berreur M, Trichet V, Pilet P, Louarn G, Layrolle P.

Eur Cell Mater. 2011 Aug 26;22:84-96; discussion 96.

34.

Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models.

Rousseau J, Escriou V, Lamoureux F, Brion R, Chesneau J, Battaglia S, Amiaud J, Scherman D, Heymann D, Rédini F, Trichet V.

J Bone Miner Res. 2011 Oct;26(10):2452-62. doi: 10.1002/jbmr.455.

35.

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.

Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S, Avet-Loiseau H.

Haematologica. 2010 Nov;95(11):1973-6. doi: 10.3324/haematol.2010.023697. Epub 2010 Jul 15.

36.

Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence.

Perrot P, Rousseau J, Bouffaut AL, Rédini F, Cassagnau E, Deschaseaux F, Heymann MF, Heymann D, Duteille F, Trichet V, Gouin F.

PLoS One. 2010 Jun 8;5(6):e10999. doi: 10.1371/journal.pone.0010999.

37.

Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models.

Rousseau J, Escriou V, Perrot P, Picarda G, Charrier C, Scherman D, Heymann D, Rédini F, Trichet V.

Cancer Gene Ther. 2010 Jun;17(6):387-97. doi: 10.1038/cgt.2009.89. Epub 2010 Jan 15.

PMID:
20075983
38.

Mcl-1(128-350) fragment induces apoptosis through direct interaction with Bax.

Ménoret E, Gomez-Bougie P, Surget S, Trichet V, Oliver L, Pellat-Deceunynck C, Amiot M.

FEBS Lett. 2010 Feb 5;584(3):487-92. doi: 10.1016/j.febslet.2009.11.094. Epub 2009 Dec 4.

39.

Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.

Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F.

Biochim Biophys Acta. 2010 Jan;1805(1):17-24. doi: 10.1016/j.bbcan.2009.08.004. Epub 2009 Sep 3. Review.

PMID:
19733222
40.

Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells.

Brounais B, David E, Chipoy C, Trichet V, Ferré V, Charrier C, Duplomb L, Berreur M, Rédini F, Heymann D, Blanchard F.

Bone. 2009 May;44(5):830-9. doi: 10.1016/j.bone.2008.12.021. Epub 2009 Jan 3.

PMID:
19168167
41.

Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.

Lamoureux F, Picarda G, Garrigue-Antar L, Baud'huin M, Trichet V, Vidal A, Miot-Noirault E, Pitard B, Heymann D, Rédini F.

Cancer Res. 2009 Jan 15;69(2):526-36. doi: 10.1158/0008-5472.CAN-08-2648.

42.

Proteases and bone remodelling.

Georges S, Ruiz Velasco C, Trichet V, Fortun Y, Heymann D, Padrines M.

Cytokine Growth Factor Rev. 2009 Feb;20(1):29-41. doi: 10.1016/j.cytogfr.2008.11.005. Epub 2008 Nov 28. Review.

PMID:
19041277
43.

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.

Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers M, Heymann D.

J Cell Mol Med. 2008 Jun;12(3):928-41. doi: 10.1111/j.1582-4934.2008.00141.x.

44.

Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.

Duplomb L, Baud'huin M, Charrier C, Berreur M, Trichet V, Blanchard F, Heymann D.

Endocrinology. 2008 Jul;149(7):3688-97. doi: 10.1210/en.2007-1719. Epub 2008 Apr 10.

PMID:
18403479
45.

Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation.

Wuillème-Toumi S, Trichet V, Gomez-Bougie P, Gratas C, Bataille R, Amiot M.

Biochem Biophys Res Commun. 2007 Oct 5;361(4):865-9. Epub 2007 Jul 24.

PMID:
17681275
46.

Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.

Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V, Blanchard F, Gouin F, Pitard B, Heymann D, Redini F.

Cancer Res. 2007 Aug 1;67(15):7308-18.

47.

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.

48.

Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53.

Chipoy C, Brounais B, Trichet V, Battaglia S, Berreur M, Oliver L, Juin P, Rédini F, Heymann D, Blanchard F.

Oncogene. 2007 Oct 11;26(46):6653-64. Epub 2007 Apr 30.

PMID:
17471233
49.

Significant impact of survivin on myeloma cell growth.

Romagnoli M, Trichet V, David C, Clément M, Moreau P, Bataille R, Barillé-Nion S.

Leukemia. 2007 May;21(5):1070-8. Epub 2007 Feb 22.

PMID:
17315024
50.

Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.

Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F.

Expert Rev Anticancer Ther. 2007 Feb;7(2):169-81. Review.

PMID:
17288528

Supplemental Content

Loading ...
Support Center